Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Moderna, Inc. (MRNA) And Encourages Investors to Reach Out
NEW YORK CITY, NY / ACCESS Newswire / October 23, 2026 /Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Moderna, Inc. ("Moderna" or "the Company") (NASDAQ:MRNA). Investors who purchased Moderna securities are encouraged to obtain additional information and assist the investigation by visiting the firm 's site: bgandg.com/cases/moderna-inc-mrna-investigation.
Moderna Investigation Details
On October 22, 2026, an early release of closely watched clinical trial results for Moderna and Merck 's joint experimental cancer vaccine appeared on the medical news website Oncology Central before being taken down shortly afterward. According to the briefly published report, combining the companies ' personalized mRNA cancer vaccine with Merck 's immunotherapy Keytruda reduced the risk of melanoma recurrence or death by 42% compared with Keytruda alone. Following this news, Moderna 's stock price dropped as much as $56.71 per share, or approximately 23.07%, during intraday trading on October 22, 2026.
What 's Next for Moderna Investors?
If you are aware of any facts relating to this investigation or purchased Moderna securities, you can assist this investigation by visiting the firm 's site: bgandg.com/cases/moderna-inc-mrna-investigation. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911
No Cost to Moderna Investors
We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys ' fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman, LLC for Moderna Securities Investigation?
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.
"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.
Follow us for updates on LinkedIn, X, Facebook, or Instagram.
Contact Info
Peretz Bronstein, Esq. or Nathan Miller
Bronstein, Gewirtz & Grossman, LLC
917-590-0911 | info@bgandg.com
Attorney advertising.
Prior results do not guarantee similar outcomes.
SOURCE:Bronstein, Gewirtz & Grossman, LLC
View the original press release on ACCESS Newswire
© 2026 ACCESS Newswire. All Rights Reserved.
